Thelifesciencesreport.com

Q3 Large Impact Drug Catalysts
Expected Start Date
Expected End Date
Expected Catalyst Title
9/30/2012 Cornerstone Therapeutics, Inc.
9/30/2012 Cornerstone Therapeutics, Inc.
8/31/2012 Titan Pharmaceuticals, Inc.
9/30/2012 Teva Pharmaceutical Industries Ltd.
9/30/2012 Cubist Pharmaceuticals, Inc.
Skin and Skin-Structure Infections (Antibacterial) Phase IV - Pediatric Safety and Efficacy Data Wet Age-Related Macular Degeneration (Wet AMD) 9/30/2012 Regeneron Pharmaceuticals, Inc.
8/31/2012 Astex Pharmaceuticals, Inc.
9/30/2012 AMAG Pharmaceuticals, Inc.
Phase III AMAG-FER-IDA-301 - Top-Line Results Phase II w/Dexamethasone - Top-Line Results 9/30/2012 Clinuvel Pharmaceuticals Ltd.
9/30/2012 Euthymics Bioscience, Inc.
Intra-Abdominal Infections (Antibacterial) Urinary Tract and Reproductive Tract Infections (Antibacterial) Development Review Phase III - 70% Fracture Outcomes Results 9/30/2012 Santen Pharmaceutical Co., Ltd.
MELAS (mitochondrial encephalopathy lactic acidosis with 9/30/2012 Senesco Technologies, Inc.
9/30/2012 Vanda Pharmaceuticals, Inc.
9/30/2012 Vertex Pharmaceuticals Incorporated 9/30/2012 RegeneRx Biopharmaceuticals, Inc.
Clostridium difficile associated Diarrhea (CDAD) 9/30/2012 Synta Pharmaceuticals Corp.
9/30/2012 Synta Pharmaceuticals Corp.
Phase II Bladder Dysfunction - Top-Line Results 7/31/2012 Generex Biotechnology Corporation 7/31/2012 HemaQuest Pharmaceuticals, Inc.
Front-line Adult AML with UK NCRI - Top-line Data Phase II - Inadequate Methotrexate Response Data 8/31/2012 Teva Pharmaceutical Industries Ltd.
Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Hepatocellular (Liver) Cancer (HCC) (including secondary 9/30/2012 Furiex Pharmaceuticals, Inc.
9/30/2012 Almirall Prodesfarma, S.A.
Dry Age-Related Macular Degeneration (Dry AMD) 9/30/2012 Sucampo Pharmaceuticals, Inc.
7/31/2012 Dainippon Sumitomo Pharma Co., Ltd.
Phase IIb ATOMIC - Non-GT 2/3 Top-line Data 9/30/2012 Hisamitsu Pharmaceutical Co., Inc.
Menopause (including Hormone Replacement Therapy [HRT]) 8/31/2012 Rigel Pharmaceuticals, Inc.
9/30/2012 Cornerstone Therapeutics, Inc.
9/30/2012 Cornerstone Therapeutics, Inc.
9/30/2012 Cornerstone Therapeutics, Inc.
7/31/2012 Discovery Laboratories, Inc.
Short Stature / Growth hormone deficiency 9/30/2012 Medigen Biotechnology Corp.
Staphylococcal Vaccines and Other Staphylococcus-Specific 9/30/2012 Neptune Technologies & Bioressources, Inc.
Q3 Large Impact Drug Catalysts
Expected Start Date
Expected End Date
Expected Catalyst Title
9/30/2012 Teva Pharmaceutical Industries Ltd.
Wet Age-Related Macular Degeneration (Wet AMD) Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Phase I/II - w/Gemcitabine - Top-line Results Brain Cancer (malignant glioma; AA and GBM) 9/30/2012 Acadia Pharmaceuticals, Inc.
9/30/2012 Achillion Pharmaceuticals, Inc.
9/30/2012 Achillion Pharmaceuticals, Inc.
Hepatocellular (Liver) Cancer (HCC) (including secondary Menopause (including Hormone Replacement Therapy [HRT]) Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease / Phase IIIb Switch from PI/r - Top-Line Results 7/31/2012 Omthera Pharmaceuticals, Inc.
Hepatocellular (Liver) Cancer (HCC) (including secondary 9/30/2012 Onyx Pharmaceuticals, Inc.
Phase III SEARCH w/Tarceva - Top-Line Data Other Ophthalmological Indications (Ophthalmology) 9/30/2012 Sunesis Pharmaceuticals, Inc.
9/30/2012 Synta Pharmaceuticals Corp.
9/30/2012 Teva Pharmaceutical Industries Ltd.
9/30/2012 Teva Pharmaceutical Industries Ltd.
9/30/2012 Watson Pharmaceuticals, Inc.
7/27/2012 Antisense Therapeutics, Ltd.
8/7/2012 Amylin Pharmaceuticals, Inc.
Bristol-Myers Acquisition of Amylin Completed Bristol-Myers Acquisition of Amylin Completed 8/31/2012 Ampio Pharmaceuticals, Inc.
Chronic Obstructive Pulmonary Disease (COPD) 7/27/2012 Onyx Pharmaceuticals, Inc.
7/30/2012 Regeneron Pharmaceuticals, Inc.
PDUFA for sNDA - 1st Review - 15 cm Patch 8/4/2012 Regeneron Pharmaceuticals, Inc.
9/30/2012 BioDelivery Sciences International, Inc.
Pivotal Bioequivalence Study (BNX-103) - Top-Line Data 9/30/2012 DUSA Pharmaceuticals, Inc.
Phase II Upper Arms/Hands - Top-Line Results 9/30/2012 Otsuka Pharmaceutical Co., Ltd.
PDUFA for sNDA - Second Review (Manufacturing) 9/8/2012 Ironwood Pharmaceuticals, Inc.
9/8/2012 Ironwood Pharmaceuticals, Inc.
Q3 Large Impact Device/Diagnostic Catalysts
Expected Start Date
Expected End Date
Expected Catalyst Title
Spinal Implants - Fixation/Plating Systems 9/30/2012 Edwards Lifesciences Corp.
Heart Valve Replacement - Bioprosthetic Valves Cortical Nerve Stimulation Devices - Neuropathic Pain 9/30/2012 Edwards Lifesciences Corp.
Heart Valve Replacement - Bioprosthetic Valves European NanoKnife System Trial (ONC-208) - Top Line Results 8/14/2012 Oculus Innovative Sciences, Inc.
FDA Clearance - Microcyn Allergen Shield HydroGel Heart Valve Repair Devices - Mitral Regurgitation (MR) 8/14/2012 American Shared Hospital Services Radiosurgery/Radiation Therapy Devices - Cancer Heart Valve Replacement - Bioprosthetic Valves Humanitarian Device Exemption - Approval Decision Cardiac Ablation Devices - Atrial Fibrillation Diagnostics - Cardiovascular Genetic Risk Tests Deep Brain Stimulation (DBS) Devices - Parkinson's Disease Diagnostics - Intravascular Ultrasound (IVUS) Q3 Large Impact Natural Resources Catalysts
Expected Start Date
Expected End Date
Expected Catalyst Title
9/30/2012 African Rainbow Minerals Limited Environmental and Social Impact Assessment - Approval Catherine Henderson A-10 Well - First Production Environmental Impact Study (EIS) Approval Environmental Impact Study (EIS) Approval Offshore Oil Drilling - United Kingdom - North Sea 9/30/2012 Aventine Renewable Energy Holdings, Inc Initial production start - 113 Million Gallons Commercial Production Start - 40,000,000 pounds/year Commerical Production Start - 20,000,000 pounds/year Drilling Completion - Total Depth 4,000 meters Production Start - 3.5 Million Ounces of Silver per Year 7/31/2012 Silver Standard Resources Inc.
7/31/2012 Silver Standard Resources Inc.
Operating Permit Approval - Clean Water Act Operating Permit Approval - Clean Water Act Operating Permit Approval - Clean Water Act Operating Permit Approval - Clean Water Act 9/30/2012 Platinum Group Metals Ltd.
9/30/2012 Platinum Group Metals Ltd.
Drill Completion and Frac'ing - Seven to Nine Wells 8/31/2012 Liberty Star Uranium & Metals Corp.
7/20/2012 Contango Oil & Gas Co.
Production Start - Sparkplug, 1,400 boe/d Resource Evaluation - Cipoeiro, Chega Tudo Ore Q3 Large Impact Natural Resources Catalysts
Expected Start Date
Expected End Date
Expected Catalyst Title
9/30/2012 Pacific Booker Minerals Inc.
9/30/2012 Pacific Booker Minerals Inc.
9/30/2012 Pacific Booker Minerals Inc.
Molybdenum Mining - British Columbia, Canada Mississippian Lime Wells 2 & 3 Completion Shallow Silver Zone - 3,000 meter Drill Program Start Shallow Silver Zone - 3,000 meter Drill Program Start Shallow Silver Zone - 3,000 meter Drill Program Start Smoke Deep Zone Exploration Drift Completion Lionfish Prospect (South Pelto 23) Production - Start 7/31/2012 Tanzanian Royalty Exploration Corp.
Exploration Drilling Program Completion - Buckreef Project 7/31/2012 Thompson Creek Metals Company Inc.
Molybdenum Mining - British Columbia, Canada Remaining 50% working interest Acquisition - Completion Western Bushveld Joint Venture - Project 2 Offshore Oil Drilling - United Kingdom - North Sea NI 43-101 Mineral Resource Estimate - Whalesback Deposit Gas Drilling - Colorado - Piceance/Uinta Basins 9/30/2012 Evolution Petroleum Corporation 9/30/2012 Evolution Petroleum Corporation 7/31/2012 FieldPoint Petroleum Corporation 7/31/2012 FieldPoint Petroleum Corporation 3D Seismic Processing & Interpretation Preliminary Economic Assessment Completion Preliminary Economic Assessment Completion 7/31/2012 Harvest Natural Resources, Inc.
7/31/2012 Harvest Natural Resources, Inc.
7/31/2012 Harvest Natural Resources, Inc.
Preliminary Economic Assessment - Pozo Seco Production Start - 10,000 oz/year after initial ramp up Davy Jones Production Start - 145 Million Cubic Feet per Day Offshore Oil Drilling - Norway - North Sea 9/30/2012 Southern Pacific Resource Corp. Well Drilling Completion - Broussard Estates #2 Well Drilling Completion - Broussard Estates #2 Preliminary Economic Assessment - Johnny Lee Preliminary Economic Assessment - Johnny Lee Acquisition of Neutron Energy - Completion Production Start - 35000 Ounces of Gold per Year Q3 Large Impact Natural Resources Catalysts
Expected Start Date
Expected End Date
Expected Catalyst Title
7/31/2012 Contango Oil & Gas Co.
7/31/2012 Contango Oil & Gas Co.
8/31/2012 Double Eagle Petroleum Co.
Production Start - Golden Bear, 30 Mmcf/d 8/31/2012 Liberty Star Uranium & Metals Corp.
8/31/2012 Paramount Gold and Silver Corp.
8/31/2012 Paramount Gold and Silver Corp.

Source: http://www.thelifesciencesreport.com/cs/user/download/co_file/3193/BioMedTracker_Healthcare_2012_Q3_Cats-By_Date.pdf